 |
|
|
 |
|
Flavonoids May Help Treat Alzheimer's
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 One expert is concerned this potential treatment could also affect a patient's cognitive functioning.
"The authors of this study believe that they have identified a drug with a reasonable safety record that could reduce both plaques and tangles," said Greg M. Cole, associate director of the Alzheimer's Disease Research Center at the UCLA David Geffen School of Medicine in Los Angeles.
However, the enzyme (GSK3) targeted by these flavonoids has many important functions, including a role in processes required for normal cognitive function, Cole said.
Text Continues Below

"In fact, complete inhibition of GSK3 causes neurons to degenerate. Since cognitive function was not evaluated in this study, researchers still need to learn how much inhibiting GSK3 will be beneficial and side effect-free. That said, this may be a promising new direction," Cole said.
Another expert cautions that promising findings in mice often do not translate into effective treatments in humans.
"While this paper also shows some promising results in amyloid-depositing mice, we know from our recent experience with Alzhemed [a drug to treat Alzheimer's] and statins that the path from 'mouse cures' to 'human cures' may be a tough path indeed," said Dr. Sam Gandy, chairman of the National Medical and Scientific Advisory Council at the Alzheimer's Association and associate director of the Mount Sinai Alzheimer's Disease Research Center at Mount Sinai School of Medicine in New York City.
"Both Alzhemed and statins were effective in mice, yet failed in the clinic, so the flavonoid data join NSAIDs, vaccines, PBT2, IVIg, secretase modulators, among others, in the queue of interventions that look promising in mice but remain to be thoroughly assessed in humans," Gandy said.
More information
For more on Alzheimer's disease, visit the Alzheimer's Association.
Page: << Prev | 1 | 2
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 5/9/2008
|
 |

SOURCES: Kavon Rezai-Zadeh, Ph.D., Rashid Laboratory for Developmental Neurobiology at Silver Child Development Center, University of South Florida, Tampa; Sam Gandy, M.D., Ph.D., chairman, National Medical and Scientific Advisory Council, Alzheimer's Association, Mount Sinai Professor of Alzheimer's Research, associate director, Mount Sinai Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York City; Greg M. Cole, Ph.D., neuroscientist, Greater Los Angeles VA Healthcare System, and associate director, Alzheimer's Disease Research Center, UCLA David Geffen School of Medicine; May 8, 2008, Journal of Cellular and Molecular Medicine, online
|